Rob is Lead Features Editor at DualShockers, and has been playing games since hijacking his sister's NES in the early 90s. Instead of outgrowing them, decided to make a life out of ranting about them.
Type I JAK2 inhibitors improve symptoms and outcomes of patients with myeloproliferative neoplasms (MPNs), but mutant allele JAK2 VF remains unchanged with this therapy. Type II JAK2 inhibitors bind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results